Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
- 29 February 2008
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 41 (2) , 154-159
- https://doi.org/10.1016/j.jcv.2007.10.003
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinicallyAIDS, 2006
- Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected PatientsHIV Research & Clinical Practice, 2006
- Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patientsAIDS, 2006
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresAIDS, 2006
- Review of atazanavir: a novel HIV protease inhibitorExpert Opinion on Pharmacotherapy, 2005
- Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyAIDS, 2004
- Atazanavir: a new protease inhibitor to treat HIV infectionAmerican Journal of Health-System Pharmacy, 2004
- Identification of I50L as the Signature Atazanavir (ATV)–Resistance Mutation in Treatment‐Naive HIV‐1–Infected Patients Receiving ATV‐Containing RegimensThe Journal of Infectious Diseases, 2004
- Human immunodeficiency virus reverse transcriptase and protease sequence databaseNucleic Acids Research, 2003
- Factors Influencing the Emergence of Resistance to Indinavir: Role of Virologic, Immunologic, and Pharmacologic VariablesThe Journal of Infectious Diseases, 1998